Jubilant Pharmova Ltd - 530019 - Announcement Under Regulation 30
Announcement under Regulation 3029-10-2022
29-10-2022
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Link of audio recording22-10-2022
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of financial results for quarter and half year ended September 202222-10-2022
Q2FY23 Quarterly Result Announced for Jubilant Pharmova Ltd.
Pharmaceuticals company Jubilant Pharmova announced Q2FY23 results: Revenues were at Rs 1,600 Crore vs. Rs 1,657 Crore in Q2'FY22 and Rs 1,452 Crore in Q1’FY23. The higher volumes in Radiopharma, Allergy and CMO Sterile injectables, API and steady growth in Drug Discovery Services led to sequential revenue growth Reported EBITDA was at Rs 232 Crore vs. Rs 344 Crore in Q2'FY22 and Rs 204 Crore in Q1’FY23. Finance cost was at Rs 42 Crore vs. Rs 35 Crore in Q2'FY22 and Rs 40 Crore in Q1’FY23. Exceptional cost of Rs 57 Crore included Rs 48 Crore of foreclosure charges related to bond repayment and balance due to write off of capitalized debt origination costs. We expect savings from lower interest rates pursuant to the refinancing will enable recovery of this cost over the tenor of the new facility Reported PAT was at Rs 5 Crore as compared with Rs 143 Crore in Q2'FY22 and Rs 47 Crore in Q1’FY23. Normalised PAT was at Rs 62 Crore as compared with Rs 143 Crore in Q2'FY22 and Rs 47 Crore in Q1’FY23. EPS was at Rs 0.34 vs. Rs 8.97 in Q2'FY22 and Rs 2.96 in Q1’FY23. Normalised EPS was Rs 3.88 vs. Rs 8.97 in Q2’FY22 and Rs 2.96 in Q1’FY23 Capital expenditure for the quarter was Rs 128 Crore Result PDF21-10-2022
Jubilant Pharmova Ltd - 530019 - Jubilant Pharmova Financial Results Q2 FY 2023
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2022 have been approved by the Board of Directors of the Company at its meeting held today at 11:45 a.m. and concluded at 1.30 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2022; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said period; and 3. Copies of the Press Release and Presentation. We request you to take the same on record.21-10-2022
Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported as per enclosed intimation letter19-10-2022
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of copies of newspaper advertisements for Postal Ballot17-10-2022
Jubilant Pharmova Ltd - 530019 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot Notice15-10-2022
Jubilant Pharmova Ltd - 530019 - Schedule Of Investor Conference Call For Jubilant Pharmova Limited - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on October 21, 2022 after submission of the financial results for the quarter and half year ended September 30, 2022 to the Stock Exchanges. Details of the Conference Call are attached.13-10-2022
Jubilant Pharmova Ltd - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - October 21, 2022
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2022 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, October 21, 2022, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2022.13-10-2022